TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Cardiovascular death, nonfatal myocardial infarction, or stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: anxiety and illness severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-report worry and intolerance of uncertainty
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fugl‐Meyer motor assessment of upper limbs active function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mRS evaluation improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OT level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite outcome of cardiac arrest or in-hospital mortality
Endpoint domain: Mortality/survival
Primary endpoint: subjective cure rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cardiac troponins T and I as markers of myocardial injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Consumption of iron-rich or iron-fortified foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of minimum dietary diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: combined incidence of all-cause hospitalization or death
Endpoint domain: Mortality/survival
Primary endpoint: Ankle brachial index improvement (DeltaABI: >0.1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maximum walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ischemic ulcers improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for tumors >= 5 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for tumors >= 10 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity for tumors >= 5 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity for tumors >= 10 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of successful anesthesia at 10 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive expression of TLR4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Impairment of barrier function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in alcohol-related behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective level of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: X-ray scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Rph during LBPP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: memory vividness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual imagery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of healthy pregnancy habits
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prenatal alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: coughing after intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IFN‐γ ELISpot response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD8+ T‐cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Env‐specific antibody responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cardiac Recovery (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart Rate Recovery (HRR(1))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Regaining continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in voiding frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in episodes of incontinence and urgency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence rate of EUGR
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in AK count from baseline to week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Rates of AKCLEAR 100 and AKCLEAR 75
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Preinjection and postinjection intraocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Vitreous hemorrhage (VR) occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Coping with pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: State of health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total Pain Index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients responding well to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase of fibrous tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Increase in the number of pulpal nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of pulp calcifications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful delivery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Average duration between induction and delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: tumor destruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Interferon response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PLT count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: calories ordered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: encouragement to exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: decreased brain activation in the left prefrontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of genes altered by α‐tocopherol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of genes altered by tocotrienol‐rich fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of hypoglycemia with plasma glucose level below 70 mg/dL per patient-year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentages of subjects with at least one unexplained hyperglycemia and/or infusion set occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: interpupillary distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: outer orbital distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of severe ARSR
Endpoint domain: Adverse events/effects
Primary endpoint: Coughing response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Recovery from urinary tract infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Bacterial susceptibility to cefixime
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety of cefixime
Endpoint domain: Adverse events/effects
Primary endpoint: Hypertension-related symptoms (headache, palpitations & chest tightness)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Microvascular reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: levels of psychopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRS (Numeric Rating Scale) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CHEOPS (Children's Hospital of Eastern Ontario Pain Scale) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene expression profiling score variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-perceived change in chest pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: numeric change in pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pacing threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Electric current
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Parent stress levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Efficacy in managing children's behaviour
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with content and delivery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: early severe heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: survival over 1 year
Endpoint domain: Mortality/survival
Primary endpoint: early repeat MI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Probability of survival 8 years after entry
Endpoint domain: Mortality/survival
Primary endpoint: Probability of disease free survival
Endpoint domain: Mortality/survival
Primary endpoint: iAUC for insulin:glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: dC3/DV at maximal dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fowler dead space (VDF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Wolff dead space (VDW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: threshold dead space (VDT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: lower RCREC in delta EEG frequencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: No complaints of vaginal discharge
Endpoint domain: Adverse events/effects
Primary endpoint: No complaints of vulvar itching/burning
Endpoint domain: Adverse events/effects
Primary endpoint: No significant increase in vulvovaginal candidiasis
Endpoint domain: Adverse events/effects
Primary endpoint: WAZ scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Continuation of antidepressant treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking cessation rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean BCVA gain from baseline to week 100
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of eyes that gained ≥15 letters from baseline at week 100
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of eyes that lost ≥15 letters at week 100
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) for glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intra-subject variability of exogenous fasting insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of hypoglycaemic episodes
Endpoint domain: Adverse events/effects
Primary endpoint: hip fracture events
Endpoint domain: Mortality/survival
Primary endpoint: Advancement of Point A (S‐Vert‐A)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in SNB angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in mandibular plane angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery from anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in the Physical Component Summary score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: decrease in blood haemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: erythrocyte transfusions
Endpoint domain: Adverse events/effects
Primary endpoint: rates of new findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rates of new findings that prompted therapeutic intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean dose-adjusted tacrolimus blood concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to reach target tacrolimus concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen radical absorbance capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: leukocyte ROCK2 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum nitric oxide concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: high sensitivity C-reactive protein (Hs-CRP) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Heart Rate Variability (HRV) time domain indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Revisions for any reason
Endpoint domain: Adverse events/effects
Primary endpoint: Osteolysis
Endpoint domain: Adverse events/effects
Primary endpoint: Understanding of patient goals
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: recurrent venous thromboembolism episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: pathologic downstaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance of Gore-Tex
Endpoint domain: Adverse events/effects
Primary endpoint: Reported carotenoid intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Skin carotenoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: length of post-operative hospitalisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-management of COPD
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical cure rate of BV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical cure rate of VVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restoration of vocal fold mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased urethral functional length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detrusor pressure at maximum flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of perineal ultrasound
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prenatal alcohol use reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total score of Rhodes questionnaire for nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total score of Rhodes questionnaire for vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attendance at the weight management clinic
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Slowing down of eating speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in AL/mo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neointimal hyperplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Improvement in physical function tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in serum phosphate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AMH serum concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction of cancellation likelihood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tonic Stretch Reflex Threshold (TSRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Unadjusted mortality
Endpoint domain: Mortality/survival
Primary endpoint: Odds of developing respiratory complications
Endpoint domain: Adverse events/effects
Primary endpoint: Favourable response (cultures negative for Mycobacterium tuberculosis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Quiescent disease at the end of 60 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 20% Paulus criteria response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 50% response duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in swollen joint count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Decreases in mycobacterial load in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: average post-treatment appetite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-treatment insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: creatinine-cystatin C-based GFR decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: progression of protein-energy insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of hepatic encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global cosmesis
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mycological cure at 72 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Global survival rate
Endpoint domain: Mortality/survival
Primary endpoint: CCE completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Colonic transit time < 40 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: DNA methylation changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Annual pregnancy rates
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of bleeding and spotting days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of dysmenorrhea, vaginitis, and myoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of menstrual disturbances (MD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estrone-1-glucuronide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pregnanediol glucuronide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cost savings per PTB averted
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Inattentiveness/Hyperactivity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall Operative Time (OpT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Micronutrient and vitamin intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dietary changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Correct classification of dysglycemia risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of positive urinary tests for recent drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak ground reaction forces during landing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daytime continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major molecular response (MR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative complete cytogenetic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes